CD55 and neoplasm: Rituximab-sensitive cell lines (Ramos and WSU-NHL) showed CDC of 47% and 38%, respectively, and 4-1H (anti-CD55 antibody) showed CDC-induced tumor cell clearance of 10% and 21%, respectively.